股本结构
单位：万股
| 公告日期 | 2025-11-14 | 2025-11-14 | 2025-08-29 | 2025-08-07 | 2025-08-07 | 2025-06-02 |
|---|---|---|---|---|---|---|
| 证券总股本 | 4760.69 | 4749.40 | 1041.11 | 1041.11 | 929.17 | 928.89 |
| 普通股本 | 4760.69 | 4749.40 | 1041.11 | 1041.11 | 929.17 | 928.89 |
| 优先股 | 未披露 | 66.76 | 0.07 | 未披露 | 4.20 | 4.20 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-10 | 2025-09-30 | 2025-08-25 | 2025-08-01 | 2025-06-30 | 2025-05-20 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-14 | 4760.69 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-11-14 | 4749.40 | 66.76 |
更多>>
From June 30,2025 to September 30,2025
Conversion of Series A Preferred Stock into common shares
Issuance of Series B Preferred Stock and warrants under private placement offering
Reclassification of Redeemable Preferred Stock to Permanent Equity upon Requisite Approval
Conversion of Series B Preferred Stock into common shares
Issuance of common stock pursuant to vesting of restricted stock units
|
2025-09-30 |
| 2025-08-29 | 1041.11 | 0.07 | 定期报告 | 2025-08-25 |
| 2025-08-07 | 1041.11 | 未披露 | 定期报告 | 2025-08-01 |
| 2025-08-07 | 929.17 | 4.20 | 定期报告 | 2025-06-30 |
| 2025-06-02 | 928.89 | 4.20 | 定期报告 | 2025-05-20 |
| 2025-05-09 | 929.17 | 4.20 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock pursuant to vesting of restricted stock units
|
2025-03-31 |
| 2025-03-31 | 928.89 | 4.20 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock pursuant to vesting of restricted stock units
Issuance of common stock for exercise of stock options
Conversion of Series A2 Preferred Stock into common shares
|
2024-12-31 |
| 2024-08-08 | 922.93 | 4.22 | 定期报告 | 2024-06-30 |
| 2024-05-30 | 922.92 | 4.22 | 定期报告 | 2024-05-02 |
| 2024-05-20 | 922.93 | 4.22 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock for exercise of stock options
|
2024-03-31 |
| 2024-03-29 | 922.55 | 未披露 | 定期报告 | 2024-03-18 |
| 2024-01-03 | 922.50 | 未披露 |
更多>>
SAB Biotherapeutics, Inc. announced 1-for-10 Reverse Stock Split.
|
2024-01-05 |
| 2023-12-18 | 9225.66 | 未披露 | 定期报告 | 2023-12-08 |
| 2023-11-13 | 5231.92 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock for exercise of stock options
|
2023-09-30 |
| 2023-08-21 | 5231.92 | 未披露 | 定期报告 | 2023-07-31 |
| 2023-08-21 | 5231.47 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock for settlement of accrued liabilities
|
2023-06-30 |
| 2023-05-15 | 5039.78 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock for exercise of stock options
|
2023-03-31 |
| 2023-02-03 | 5039.78 | 未披露 | 定期报告 | 2023-01-31 |
| 2023-04-14 | 5039.43 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock and warrants under private placement offering, net of issuance costs of $0.3 million
Issuance of common stock for exercise of stock options
Repurchase of common stock pursuant to the Forward Share Purchase Agreement
|
2022-12-31 |
| 2022-12-16 | 5039.43 | 未披露 | 定期报告 | 2022-12-16 |
| 2022-08-10 | 4303.09 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock for exercise of stock options
|
2022-06-30 |
| 2022-05-25 | 4298.76 | 未披露 | 定期报告 | 2022-05-23 |
| 2022-05-12 | 4296.21 | 未披露 | 定期报告 | 2022-04-28 |
| 2022-05-12 | 4295.51 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock for exercise of stock options
Repurchase of common stock pursuant to the Forward Share Purchase Agreement
|
2022-03-31 |
| 2022-03-29 | 4295.51 | 未披露 | 定期报告 | 2022-03-28 |
| 2022-03-29 | 4348.73 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Effect of Business Combination and recapitalization, net of redemptions and issuance costs of $3,294,096
Issuance of restricted stock, subject to forfeiture
Issuance of common stock for exercise of stock options
|
2021-12-31 |
| 2021-11-22 | 4347.48 | 未披露 | 定期报告 | 2021-11-15 |
| 2021-09-24 | 2970.30 | 未披露 | 定期报告 | 2021-10-25 |
| 2021-10-28 | 4347.48 | 未披露 | 定期报告 | 2021-10-22 |
| 2021-05-21 | 1479.22 | 未披露 |
更多>>
from January 1, 2021 to March 31, 2021
Sale of 11,500,000 Units, net of underwriting discount and offering expenses
Sale of 417,200 Private Units
Common stock subject to possible redemption
|
2021-03-31 |
| 2021-04-02 | 1479.22 | 未披露 | 定期报告 | 2021-03-29 |
| 2021-01-12 | 1288.23 | 未披露 | 定期报告 | 2021-02-09 |
From June 30,2025 to September 30,2025
Conversion of Series A Preferred Stock into common shares
Issuance of Series B Preferred Stock and warrants under private placement offering
Reclassification of Redeemable Preferred Stock to Permanent Equity upon Requisite Approval
Conversion of Series B Preferred Stock into common shares
Issuance of common stock pursuant to vesting of restricted stock units
From December 31, 2024 to March 31, 2025
Issuance of common stock pursuant to vesting of restricted stock units
From December 31, 2023 to December 31, 2024
Issuance of common stock pursuant to vesting of restricted stock units
Issuance of common stock for exercise of stock options
Conversion of Series A2 Preferred Stock into common shares
From December 31, 2023 to March 31, 2024
Issuance of common stock for exercise of stock options
SAB Biotherapeutics, Inc. announced 1-for-10 Reverse Stock Split.
From June 30, 2023 to September 30, 2023
Issuance of common stock for exercise of stock options
From March 31, 2023 to June 30, 2023
Issuance of common stock for settlement of accrued liabilities
From December 31, 2022 to March 31, 2023
Issuance of common stock for exercise of stock options
From December 31, 2021 to December 31, 2022
Issuance of common stock and warrants under private placement offering, net of issuance costs of $0.3 million
Issuance of common stock for exercise of stock options
Repurchase of common stock pursuant to the Forward Share Purchase Agreement
From March 31, 2022 to June 30, 2022
Issuance of common stock for exercise of stock options
From December 31, 2021 to March 31, 2022
Issuance of common stock for exercise of stock options
Repurchase of common stock pursuant to the Forward Share Purchase Agreement
From December 31, 2020 to December 31, 2021
Effect of Business Combination and recapitalization, net of redemptions and issuance costs of $3,294,096
Issuance of restricted stock, subject to forfeiture
Issuance of common stock for exercise of stock options
from January 1, 2021 to March 31, 2021
Sale of 11,500,000 Units, net of underwriting discount and offering expenses
Sale of 417,200 Private Units
Common stock subject to possible redemption